What is the Wesfarmers Infinity sale and why does it matter?

The Wesfarmers Infinity sale refers to a potential process involving assets tied to Infinity Pharmacy Group’s collapse, intersecting with Priceline-linked sites. It matters because prices set in this process affect recoveries, potential write-downs at API, and the competitive landscape in pharmacy retail, which can influence WES.AX valuation and earnings expectations.

How does Infinity Pharmacy receivership affect API within Wesfarmers?

Infinity Pharmacy receivership introduces uncertainty around leases, supplier terms, and store transfers. That uncertainty can impact API’s provisions, cash flows, and near-term earnings. Clear sale outcomes, better visibility on creditor recoveries, and franchise stability would lower risk. Investors will look for disclosures at Wesfarmers’ 18 February 2026 results.

What trading levels and dates should WES.AX investors watch next?

Key levels include support near A$80.15 and resistance around A$82.08 to A$83.29. The 50-day average sits near A$81.26 and the 200-day near A$84.69. With ADX around 14, trend is weak and moves may be headline-driven. The next major date is 18 February 2026 for Wesfarmers’ earnings.

Global Market Insights

WES.AX Stock Today: January 22 Infinity Sale Prep, Priceline Fallout

ByHuzaifa Zahoor January 22, 2026January 22, 2026

Investors in WES.AX are focused on the Wesfarmers Infinity sale after reports that Chemist Warehouse and private equity are preparing for a process following the collapse of Infinity Pharmacy Group. With 54 Priceline stores in receivership and creditors reportedly owed over A$400 million, attention turns to potential recoveries versus write-down risk at API, Wesfarmers’ health unit. We outline the competitive stakes, what to watch into 18 February 2026 earnings, and the key trading levels shaping sentiment in Australia’s pharmacy retail market.